[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"German Diabetes Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":181},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,47,77,103,126,147],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100622852","exercise-chronotype-and-prediabetes-100622852",false,"NCT07389005","Exercise, Chronotype, and Prediabetes","Timed Exercise in Prediabetes With Extreme Chronotype","Inclusion Criteria:\n\n1. Able to provide signed and dated written informed consent prior to any study specific procedures\n2. Adult men and women aged between more than 18 and ≤ 75 years\n3. Body mass index (BMI) of 25 - 35 kg\u002Fm2\n4. Stable weight (no weight loss or gain \\> 3 kg in the past 3 months)\n5. Pre-diabetes defined as an isolated impaired glucose tolerance or a combination of impaired glucose tolerance and impaired fasting glucose (values are based on the American Diabetes Association (ADA):\n\n   1. impaired glucose tolerance (plasma glucose 140 mg\u002FdL to 199 mg\u002FdL, 120 minutes after consumption of 75g of glucose)\n   2. impaired fasting glucose (fasting plasma glucose 100 mg\u002FdL to 125 mg\u002FdL)\n6. Morning (Morningness-Eveningness Questionnaire \\[MEQ\\] score ≥ 59) or evening (MEQ score ≤ 41) chronotype\n\nExclusion Criteria:\n\n1. Previously diagnosed with type 2 diabetes\n2. Moderate to severe anemia (hemoglobin \\\u003C 10 g\u002FL)\n3. Uncontrolled hypertension\n4. Abnormal electrocardiogram (ECG) at rest judged by the study physician\n5. Pregnancy or breastfeeding\n6. HIV, hepatitis B, or C infection\n7. Disorders of blood clotting or wound healing\n8. Positive history of venous thrombosis (contraindication for clamp)\n9. Hypersensitivity to local anesthetics (contraindication for fat\u002Fmuscle biopsies)\n10. Night shift work in the last 3 months\n11. Travel across \\> 1 time zone in the last 3 months\n12. Participation in another clinical trials that may possibly hamper the study results\n13. Engagement in structured exercise activities \\> 2 hours a week\n14. Any acute condition, exacerbation of chronic condition, or medical history that in the investigator's opinion would interfere with the study\n15. Any contraindication for MRI scanning\n16. Medication use known to hamper safety during the study procedures\n17. Non-German speaking","ALL","19 Years","75 Years",{"count":20,"type":21},28,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to find out whether exercising at the right time of day, based on a person's natural body clock, leads to greater health benefits in people living with prediabetes. The main question it aims to answer is whether doing a single session of exercise in the morning or in the evening affects how the body handles sugar differently in adults with prediabetes who have an extreme natural body clock. This will be done by comparing three conditions (no-exercise, morning exercise, and evening exercise) within the same participant. Each condition will be tested on a different day, with at least 14 days between the test days. During the no-exercise test days, participants will come to the study centre and will only be allowed to do sedentary activities (e.g. office work, reading, or screen time). During the morning exercise test days, participants will perform an exercise session at 9:00 am that involves short periods of very hard effort followed by short rest periods. Whereas for the evening exercise test days, the same type of exercise will be performed at 5:00 pm.",[27,28],"Prediabetes","Overweight , Obesity",[27,30,31,32,33],"Overweight","Obesity","Exercise","Chronotype","NOT_YET_RECRUITING","2026-01-28",{"date":37,"type":38},"2026-02-05","ACTUAL",{"date":40,"type":21},"2026-02",{"date":42,"type":21},"2028-08",{"name":44,"class":45},"German Diabetes Center","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":16,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":46},"100137098","prospective-study-on-diabetes-mellitus-and-its-complications-in-newly-diagnosed-adult-patients-100137098","NCT01055093","Prospective Study on Diabetes Mellitus and Its Complications in Newly Diagnosed Adult Patients","GDC","Inclusion Criteria:\n\n* Clinical diagnosis of diabetes mellitus according to ADA criteria\n* Age 18-69\n* Diabetes duration since diagnosis \\\u003C 12 months\n* Control cohort: proven normal glucose tolerance according to ADA criteria\n\nExclusion Criteria:\n\n* Diabetes mellitus category 3 B-H (ADA criteria)\n* Pregnancy\n* Severe renal, liver or heart disease\n* malignant cancer\n* severe psychiatric illness or addiction\n* participation in an intervention trial",true,"18 Years","69 Years",{"count":58,"type":21},2000,"OBSERVATIONAL","The aim of the prospective observational GDC-Study in patients with newly diagnosed diabetes mellitus aged 18-69 years at inclusion into the study is to characterize in detail the clinical, metabolical and immunological phenotype and monitor the progression of the disease and to compare the phenotype to glucose tolerant humans of similar age, body mass and sex distribution.",[62,63],"Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2",[65,66,67],"diabetes mellitus","prospective observational study","diabetic complications","RECRUITING","2025-07-12",{"date":71,"type":38},"2025-07-16",{"date":73,"type":38},"2005-09",{"date":75,"type":21},"2040-09",{"name":44,"class":45},{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":54,"sex":16,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":89,"conditions":90,"keywords":91,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":46},"100169342","the-effect-of-bariatric-surgery-on-insulin-sensitivity-and-energy-metabolism-100169342","NCT01477957","The Effect of Bariatric Surgery on Insulin Sensitivity and Energy Metabolism","The Effect of Bariatric Surgery on Insulin Sensitivity and Energy Metabolism in Obesity Grade 2 -3","BARIA-DDZ","Inclusion Criteria:\n\n* Aged ≥ 20 years- ≤ 70 years\n* BMI 20- 25 kg\u002Fm 2 normal- weight group\n* BMI 35- 39,9 kg\u002Fm 2 (Obesity grade 2)\n* BMI \\>40 kg\u002Fm 2 (Obesity grade 3)\n\nExclusion Criteria:\n\n* Acute illness 2 weeks before start of examination\n* Autoimmune or Immune disorder diseases (Leukozyten \\\u003C 5000\u002Fµl\n* Renal insufficiency (Kreatin \\> 1,5 mg\u002Fdl)\n* Heart disease, condition after heart attack\n* Anemia (Hb \\\u003C12g\u002Fl, controlled before every day of examination) or blood donations 4weeks before examination.\n* Participation in another trial within the last 2 weeks\n* Pharmacological- immunotherapy (Cortisol, Antihistaminika, ASS)\n* Thyroid disorders\n* Glitazone Therapy\n* Pregnancy, Lactation, Menstruation\n* Smoking cigarettes, Alcohol- and drug abuse\n* Psychiatric disorders\n* Risk for\u002F or diagnosed HIV\u002F AIDS or Hepatitis B\u002FC\n* Liver disease, which are not caused by non- alcoholic steato- hepatitis\n* Working on night shifts or irregular rhythm of night- day\n* Impaired wound healing or clotting disorders\n* Allergic reaction to local anesthetics\n* Malignant cancer","20 Years","70 Years",{"count":88,"type":21},450,"The purpose of this study is:\n\n1. To explore to what extent insulin sensitivity, energy metabolism and ectopic lipid storage can be improved by bariatric surgery\n2. To explore to what extent hepatic and muscular disorders of energy metabolism occur in patients with obesity (degree 2-3)\n3. To explore whether the steato liver occurring in patients with obesity (degree 2-3) is associated with the degree of liver inflammation",[31,63],[92,93,94],"weight loss after bariatric surgery","Insulin sensitivity","insulin resistance","2025-01-09",{"date":97,"type":38},"2025-01-10",{"date":99,"type":4},"2012-09",{"date":101,"type":21},"2028-12",{"name":44,"class":45},{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":54,"sex":16,"minAge":55,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":22,"phases":114,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":46},"100530967","overfeeding-induced-fat-tissue-stimulation-100530967","NCT06193668","Overfeeding Induced Fat-tissue Stimulation","Short-term High-fat Overnutrition Induces Insulin Resistance in White Adipose Tissue","OVID_FASTI","Inclusion Criteria:\n\n* Age between 18 and 40 years\n* BMI \\\u003C 29 kg\u002Fm2\n* Sport inactive (\\\u003C1x \u002Fweek)\n* Capacity to consent\n\nExclusion Criteria:\n\n* Diabetes mellitus disease\n* Acute coronary heart syndrome (myocardial infarction, unstable angina pectoris, stroke or transient ischemic attack in the last 3 months before study participation)\n* Acute infectious disease\n* Taking blood glucose-lowering drugs\n* Diseases or drugs affecting the immune system and allergies to drugs used in the study\n* Drugs with potential metabolic effects\n* Chronic liver disease (hepatitis, gallbladder disease, elevated liver enzymes (ALT \\> 300 U\u002FL))\n* Chronic inflammatory bowel diseases\n* Rheumatic diseases\n* Hyper- or hypothyroidism of the thyroid gland\n* Renal insufficiency, administration of iodine-containing contrast media in the last 2 days\n* Chronic lung diseases\n* cancerous diseases\n* Addictive diseases, psychiatric diseases\n* Pregnancy, breastfeeding\n* Shift workers\n* Anemia (Hb \\\u003C12 g\u002Fdl)\n* Disorders of hemostasis\n* Regular use of antithrombotic drugs\n* Alcohol consumption, smoking\n* Conditions that do not permit an MRI examination","40 Years",{"count":113,"type":21},32,[24],"Type 2 diabetes is the most common metabolic disease worldwide, characterized by hyperglycemia, decreased whole body insulin sensitivity, and white adipose tissue (WAT) dysfunction. A key factor in its development is chronic overnutrition, usually with a high-fat diet (HFD), leading to disturbances of glucose and lipid metabolism. However, the mechanism of short-term HFD-induced tissue-specific insulin resistance remains poorly understood. This project aims to further unravel the underlying mechanisms of short-term HFD overnutrition-mediated WAT insulin resistance. The model described here corresponds to a randomized, single- blinded parallel-grouped trial, consisting of two interventions: a macronutrient-balanced diet and or a hypercaloric diet over three weeks in order to investigate differences in interorgan fatty acid and glucose metabolism between the studied groups. Based on recent studies, the hypothesis is that 21-day hypercaloric HFD induces WAT insulin resistance via a diacylglycerol, novel protein kinase C-insulin receptor signaling model in both fasting and insulin-stimulated states.",[117],"Lipid-induced Insulin Resistance","2024-02-29",{"date":120,"type":38},"2024-03-01",{"date":122,"type":38},"2024-01-31",{"date":124,"type":21},"2030-12-31",{"name":44,"class":45},{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":136,"conditions":137,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":46},"100527663","study-on-pancreatic-islets-in-patients-undergoing-partial-pancreatectomy-precise-100527663","NCT06150690","Study on Pancreatic Islets in Patients Undergoing (Partial) Pancreatectomy (PRECISE)","Study on the Function of Insulin-producing Beta Cells in the Human Pancreas","PRECISE","Inclusion Criteria:\n\nability to give informed consent\n\nExclusion Criteria:\n\ndenial of informed consent",{"count":135,"type":21},400,"The study investigates the mechanisms underlying the pathogenesis of diabetes by examining structural and functional properties of islets of Langerhans in pancreas specimen from patients undergoing (partial) pancreatectomy.",[138],"Diabetes Mellitus","2023-11-27",{"date":141,"type":38},"2023-11-29",{"date":143,"type":38},"2012-08-21",{"date":145,"type":21},"2035-12-31",{"name":44,"class":45},{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":54,"sex":16,"minAge":55,"maxAge":155,"enrollmentInfo":156,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":158,"conditions":159,"keywords":163,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":46},"100442830","metabolic-phenotyping-and-follow-up-of-patients-with-and-without-diabetes-after-new-onset-of-stemi-100442830","NCT05046483","Metabolic Phenotyping and Follow-Up of Patients With and Without Diabetes After New Onset of STEMI","Metabolic Phenotyping and Follow-Up of Patients With and Without Diabetes Mellitus After New Onset of ST-Segment Elevation Myocardial Infarction (STEMI) (DISTEMI Study)","DISTEMI","Inclusion Criteria:\n\n* Condition after new onset of ST-segment elevation myocardial infarction (STEMI)\n* Age 18-80 years\n* HbA1c \\\u003C9.0%\n* People with diagnosis of diabetes mellitus according to ADA and DDG criteria (i.e. HbA1c ≥6.5% and\u002For pathological oral glucose tolerance test)\n* Healthy people with normal glucose tolerance status according to ADA and DDG criteria (i.e. HbA1c \\\u003C5.7% and normal OGTT)\n* People with impaired glucose metabolism (\"prediabetes\") according to ADA and DDG criteria (i.e. impaired fasting glucose and\u002For impaired glucose tolerance and\u002For HbA1c 5.7-6.4%)\n* Consent-able, hemodynamically stable people, without sedation (e.g. opiates) or other interfering medication (e.g. catecholamines)\n\nExclusion Criteria:\n\n* Diabetes mellitus category 3 A-H (ADA criteria), gestational diabetes\n* Current pregnancy\n* Infectious diseases, acute infections \u002F fever\n* Immunosuppressive therapy\n* Severe chronic renal, liver or heart disease (e.g. serum creatinin ≥1.6 mg\u002Fdl, peripheral artery occlusive disease stage IV)\n* Malignant diseases\n* Severe chronic psychiatric illness or addiction\n* Participation in an intervention trial","80 Years",{"count":157,"type":21},300,"The aim of the prospective observational DISTEMI-Study in people with and without Diabetes mellitus (DI) after new onset of ST-Segment Elevation Myocardial Infarction (STEMI) aged 18-80 years at inclusion into the study is to characterize in detail the clinical, metabolical, immunological and vascular phenotype, investigate the interplay between myocardial remodelling and the metabolic phenotype, monitor the progression of the disease and compare the phenotype of STEMI people with diabetes mellitus to people with prediabetes and glucose tolerant people.",[160,138,161,162],"ST-segment Elevation Myocardial Infarction (STEMI)","Insulin Resistance","Non-Alcoholic Fatty Liver Disease",[164,165,166,167,168,169,170,171,172],"ST-segment elevation myocardial infarction","STEMI","Cardiovascular diseases","CVD","Diabetes mellitus","Normal glucose tolerance","Non-alcoholic fatty liver disease","NAFLD","Liver fibrosis","2023-08-17",{"date":175,"type":38},"2023-08-22",{"date":177,"type":38},"2018-12-30",{"date":179,"type":21},"2029-12-30",{"name":44,"class":45},""]